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Controlled release and angiotensin-converting enzyme inhibition properties of an 
antihypertensive drug based on a perindopril erbumine-layered double hydroxide 
nanocomposite. 
 
ABSTRACT 
The intercalation of perindopril erbumine into Zn/Al-NO3-layered double hydroxide resulted 
in the formation of a host-guest type of material. By virtue of the ionexchange properties of 
layered double hydroxide, perindopril erbumine was released in a sustained manner. 
Therefore, this intercalated material can be used as a controlled-release formulation. Results: 
Perindopril was intercalated into the interlayers and formed a well ordered, layered organic-
inorganic nanocomposite. The basal spacing of the products was expanded to 21.7 Å and 19.9 
Å by the ion-exchange and coprecipitation methods, respectively, in a bilayer and a 
monolayer arrangement, respectively. The release of perindopril from the nanocomposite 
synthesized by the coprecipitation method was slower than that of its counterpart synthesized 
by the ion-exchange method. The rate of release was governed by pseudo-second order 
kinetics. An in vitro antihypertensive assay showed that the intercalation process results in 
effectiveness similar to that of the antihypertensive properties of perindopril. Conclusion: 
Intercalated perindopril showed better thermal stability than its free counterpart. The resulting 
material showed sustained-release properties and can therefore be used as a controlled-release 
formulation. 
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